SCHEMBL6584469

SCHEMBL6584469

Cn1cncc1C(O)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cn2S(C)(=O)=O

nearest known ligand 0.72

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
FNTA P49354 12/20 0.72
FNTB P49356 12/20 0.72
RORC P51449 5/20 0.54
PGGT1B P53609 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6587157 0.88 FNTA (0.66) FNTAFNTBPGGT1B
SCHEMBL6585965 0.86 FNTA (0.72) FNTAFNTBRORCPGGT1B
SCHEMBL13928075 0.84 FNTA (1.00) FNTAFNTB
SCHEMBL1682772 0.84 FNTA (1.00) FNTAFNTB
SCHEMBL6789898 0.84 FNTA (0.69) FNTAFNTBRORCPGGT1B
Hydrochloric Acid SCHEMBL6435591 0.83 FNTA (0.98) FNTAFNTB
SCHEMBL6602862 0.82 FNTA (0.53) FNTAFNTBRORCPGGT1B
SCHEMBL5654543 0.82 FNTA (0.96) FNTAFNTB
SCHEMBL6587417 0.82 FNTA (0.67) FNTAFNTBRORCPGGT1B
SCHEMBL6586542 0.81 FNTA (0.63) FNTAFNTBRORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1420015-A1 Imidazolyl derivatives SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) 2004-05-19 EP disclosed
EP-1097150-B1 IMIDAZOLYL DERIVATIVES CONSEILS DE RECH SET D APPLIC (FR) 2004-03-24 EP disclosed
US-20040002531-A1 Imidazolyl derivatives SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTEFIQUES, S.A.S., A FRANCE CORPORATION 2004-01-01 US disclosed
US-6509336-B1 Prenyl transeferase inhibitors SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) 2003-01-21 US disclosed
US-20030004342-A1 Imidazolyl derivatives BIOMEASURE, INC., A MASSACHUSETTS CORPORATION 2003-01-02 US disclosed
US-6420555-B1 IMIDAZOLE DERIVATIVES PRENYL TRANSFERASE INHIBITORS. SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) 2002-07-16 US disclosed
EP-1097150-A1 IMIDAZOLYL DERIVATIVES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) 2001-05-09 EP disclosed
EP-1094810-A1 USE OF PRENYLTRANSFERASE INHIBITORS FOR PREPARING A MEDICINE FOR TREATING PATHOLOGIES RESULTING FROM HETEROTRIMERIC G PROTEIN MEMBRANE FIXATION SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2001-05-02 EP disclosed
WO-2000002558-A1 USE OF PRENYLTRANSFERASE INHIBITORS FOR PREPARING A MEDICINE FOR TREATING PATHOLOGIES RESULTING FROM HETEROTRIMERIC G PROTEIN MEMBRANE FIXATION SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2000-01-20 WO disclosed
WO-1999065898-A1 IMIDAZOLYL DERIVATIVES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES SAS (FR) 1999-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004342-A1 Imidazolyl derivatives TPI1, BCHE, CYP51A1 FNTA 51/4885FNTB 184/4885RORC 1358/4885
US-20040002531-A1 Imidazolyl derivatives TPI1, BCHE, CYP51A1 FNTA 51/4885FNTB 184/4885RORC 1358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.